Large Osteoclasts in Pediatric Osteogenesis Imperfecta Patients Receiving Intravenous Pamidronate

Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (01). Changes in the appearance of osteoclasts have previously been noted in children receiving pamidronate and have been interpreted as signs of toxicity. In this study, we analyzed osteoclast parameters in paired iliac bone specimens before and after 2-4 yr of cyclical intravenous pamidronate therapy in 44 pediatric OI patients (age range: 1.4-17.5 yr; 21 girls). During pamidronate treatment, average osteoclast diameter and the mean number of nuclei present per osteoclast increased by 18% (p=0.02) and 43% (p<0.001), respectively. The number of samples containing large osteoclasts (LOcs, diameter >50 mu m) increased from 6 (14%) before treatment to 23 (52%) after pamidronate therapy (p<0.001 by chi(2) test). Post-treatment samples containing LOcs had a greater core width (p=0.04) and a higher cancellous bone volume per tissue volume (p<0.001), because cancellous bone volume had increased more during pamidronate treatment (p<0.001). Osteoclast number and surface were higher in samples with LOcs, but there was no difference in cancellous bone formation parameters. The presence of LOcs was independent of Of type, type of collagen type I mutation, lumbar spine BM D, and other clinical or biochemical measures. In conclusion, this study did not show any indication that LOcs during pamidronate treatment are indicative of toxicity. It seems more likely that the observed abnormalities in osteoclast morphology are part of the mechanism of action of this drug.